64
Participants
Start Date
May 15, 2017
Primary Completion Date
March 12, 2019
Study Completion Date
March 4, 2021
Bosutinib
All patients will receive bosutinib at a starting dose of 400 mg QD.
Fujita Health University Hospital, Toyoake
Toyohashi Municipal Hospital, Toyohashi
Akita University Hospital, Akita
Japanese Red Cross Narita Hospital, Narita
Ehime University Hospital, Toon-shi
Kobe City Medical Center General Hospital, Kobe
Ishikawa Prefectural Central Hospital, Kanazawa
Yokohama City University Medical Center, Yokohama
National Hospital Organization Osaka Minami Medical Center, Kawachi-Nagano
Osaka City University Hospital, Osaka
Kindai University Hospital, Ōsaka-sayama
Hamamatsu University Hospital, Hamamatsu
Juntendo University Hospital, Bunkyo-ku
Tokyo Metropolitan Cancer and Infectious diseases Center Komagome Hospital, Bunkyo-ku
NTT Medical Center Tokyo, Shinagawa-ku
National Hospital Organization Disaster Medical Center, Tachikawa
Yamagata University Hospital, Yamagata
Chiba University Hospital, Chiba
National Hospital Organization Kyushu Cancer Center, Fukuoka
Saga University Hospital, Saga
Nippon Medical School Hospital, Tokyo
Lead Sponsor
Pfizer
INDUSTRY